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Lentviral-mediated RNAi to inhibit target gene
expression of the porcine integrin av subunit,
the FMDV receptor, and against FMDV infection
in PK-15 cells




Background: shRNA targeting the integrin av subunit, which is the foot-and-mouth disease virus (FMDV) receptor, plays
a key role in virus attachment to susceptible cells. We constructed a RNAi lentiviral vector, iav pLenti6/BLOCK -iT™,
which expressed siRNA targeting the FMDV receptor, the porcine integrin av subunit, on PK-15 cells. We also produced a
lentiviral stock, established an iav-PK-15 cell line, evaluated the gene silencing efficiency of mRNA using real-time qRT-
PCR, integrand av expression by indirect immunofluorescence assay (IIF) and cell enzyme linked immunosorbent assays
(cell ELISA), and investigated the in vivo inhibitory effect of shRNA on FMDV replication in PK-15 cells.
Results: Our results indicated successful establishment of the iav U6 RNAi entry vector and the iav pLenti6/BLOCK
-iT expression vector. The functional titer of obtained virus was 1.0 × 10
6 TU/mL. To compare with the control and
mock group, the iav-PK-15 group av mRNA expression rate in group was reduced by 89.5%, whilst IIF and cell ELISA
clearly indicated suppression in the experimental group. Thus, iav-PK-15 cells could reduce virus growth by more
than three-fold and there was a > 99% reduction in virus titer when cells were challenged with 10
2 TCID50 of FMDV.
Conclusions: Iav-PK-15 cells were demonstrated as a cell model for anti-FMDV potency testing, and this study
suggests that shRNA could be a viable therapeutic approach for controlling the severity of FMD infection and spread.
Background
Foot-and-mouth disease virus (FMDV) is a picornavirus,
which causes a highly contagious disease in cloven-
hoofed animals. Foot-and-mouth disease (FMD) is a
threat to the worldwide livestock industry, because FMD
can have a devastating effect on a country’se c o n o m y .
FMDV shows a high genetic and antigenic variability,
which is reflected in the seven serotypes and numerous
variants described to date [1]. The FMDV genome is
composed of a positive-sense single-stranded RNA mole-
cule of about 8 500 nucleotides, which contains a unique
open reading frame. There are seven distinguishable ser-
ological types, i.e., O, A, C, Asia1, SAT1, SAT2, and
SAT3, and more than 65 subtypes.
Recently, RNAi has shown promise as a therapeutic in
many infections, including, viral diseases of animals and
humans. RNAi is a process of sequence specific, post-
transcriptional gene silencing (PTGS) in animals and
plants, which is conducted using 21 to 33 nucleotides
(nt) of small interfering RNA (siRNA), which are homo-
logous in sequence to the silenced gene [2]. In eukaryotic
organisms, dsRNA is produced in vivo or introduced by
pathogens and processed into 21-23 nucleotide double-
stranded short interfering RNA duplexes (siRNA) using
an enzyme called Dicer, which is a member of the RNase
III family of double-stranded RNA-specific endonu-
cleases [3,4]. Each siRNA ia then incorporated into an
RNA-induced silencing complex (RISC), which is an
enzyme complex used to target cellular transcripts com-
plementary to the siRNA for specific cleavage and degra-
dation [5,6]. In addition to dsRNA, other endogenous
RNA molecules have been shown to be capable of
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any medium, provided the original work is properly cited.triggering gene silencing, including, short temporal RNA
(stRNA) and microRNA (miRNA) [7].
RNAi has been widely studied as an antiviral technology
for combating FMDV [8,9]. FMDV is antigenically variable,
undergoing rapid mutation, which allows it to easily escape
t h eh o s ti m m u n es y s t e mv i at h eh i g hv a r i a b i l i t yo fi t s
surface antigens. Existing vaccines and antiviral drugs have
limited effectiveness, so the development of new strategies
is essential. High genetic variability is a major issue that
must be addressed in order to establish RNAi as a viable
approach against FMDV [10]. Current measures for the
control of FMDV replication include, RNAi plasmid 1D or
3D [11], VP1 [9], IRES [12], all of which are focused on
several regions of the FMDV genome [13]. RNAi directed
at specific gene sequences of certain FMDV strains might
be a risky strategy, especially in the event of an emergent
FMD outbreak in the absence of information concerning
the serotype or genotype of the isolated pathogen, although
early protection is needed. The integrin av subunit is the
FMDV receptor for each serotype or genotype and the
integrin av subunit of the FMDV receptor plays a key role
in the attachment of the virus to susceptible cells. Studies
have shown a clear correlation between sensitivity of
FMDV and expression of integrins avb1, avb3, avb6, and
avb8. Most integrin subunits have independent functions
and are essential for normal development [14,15]. a1-null
mice are viable, fertile and apparently normal, whereas a7-
null mice develop muscular dystrophy, and a9-null mice
die within 10 day of birth. Mutations in many of the
ligands for av integrins are also viable. Thus, although
many of these ligands and av integrins are widely
expressed during development, they do not appear to be
essential [16,17]. In this study, we used “knockdown”
rather than “knockout” target gene expression of the por-
cine integrin av subunit, the FMDV receptor, to establish
a cell line that could inhibit FMDV replication. Therefore,
our work on RNAi with FMDV is a step forward on all
previous work, particularly with respect to the cell model
system.
In this study, we constructed an RNAi lentiviral vector
that inhibited target gene expression of the porcine integ-
rin av subunit and the FMDV receptor in PK-15, and
F M D Vr e p l i c a t i o ni ni av-PK-15. The vector was capable




293T cells and PK-15 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM, GIBCO™, Invitrogen
Corporation, Grand Island, NY, USA) supplemented
with 10% heat-inactivated fetal bovine serum (FBS) (pH
7.4). Cultures were incubated at 37°C with 5% CO2.
FMDV O/CHA/99 [GenBank accession number
AF506822] was used for viral challenge.
Construction of Lentivirus vector and establishment of
the iav-PK-15 cell line





was chemically designed and synthesized by the Invitro-
gen Corporation, and the ds oligo was cloned into the lin-
earized pENTR™/U6 vector. The pENTR™/U6 entry
vector provides a rapid and efficient way to clone oligo
duplexes encoding a desired shRNA target sequence into a
vector containing an RNA Pol III-dependent expression
cassette for use in RNAi analysis. We generate an iav-
pLenti6/BLOCK-iT™ expression clone construct using an
LR recombination reaction between the iav-pENTR™/U6
entry clone and the pLenti6/BLOCK-iT™-DEST vector
(Figure 1). We used the expression clone construct and
the LR clonase enzyme mix to produce a lentiviral con-
struct. We co-transfected the 293FT producer cell line
with three optimized packaging plasmids (pLP1, pLP2,
and pLP/VSVG) and the iav-pLenti6/BLOCK-iT™
expression clone construct, which resulted in production
of lentiviral stocks with a suitable titer. Stably transduced
PK-15 cells were selected using blasticidin, with the mini-
mum concentration of blasticidin required to kill untrans-
duced PK-15 cells. The following procedure was used to
determine the titer of the lentiviral stock using the PK-15
cells. To set up the stable cell line selection, we first
needed to produce a lentiviral stock (iav-PK-15 containing
the packaged iav pLenti6/BLOCK-iT™-DEST expression
construct and a control containing the packaged pLenti6/
BLOCK-iT™-DEST expression construct) by co-transfect-
ing the optimized ViraPower™ packaging mix or pLenti6/
BLOCK-iT™-DEST expression construct into the 293FT
producer cell line. PK-15 cell cultures were incubated at
37°C with 5% CO2. The day before transduction, cells
were trypsinized, diluted with DMEM fresh medium, and
seeded into 6-well culture plates. On the day of transduc-
tion (day one), when PK-15 cells were about 80% conflu-
ent, we thawed the lentiviral stock and diluted the
appropriate amount of virus (MOI = 5) into fresh DMEM
complete medium. The culture medium was removed
from the cells. The medium containing virus was gently
mixed by pipetting and added to the cells. Polybrene was
added to a final concentration of 6 μg/mL. Cells were
incubated for approximately six hours prior to changing
the medium. The following day (day two), the medium
containing virus was removed and replaced with fresh,
complete culture medium. The following day (day three),
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complete medium containing the appropriate amount of 2
μg/mL blasticidin to select for stably transduced cells.
Selection took up to two weeks. At some point there was a
massive cell death and most of the cells were washed from
the bottom of the dish, leaving colonies of stable cells
behind. Blasticidin-resistant colonies were picked using a
Gilson pipette with a sterile tip, by lowering the tip to the
surface of the colony of interest then scraping and sucking
gently until they were pulled into the tip. Colonies were
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Figure 1 Construction of iav-pLenti6/BLOCK-iT Expression Construct.
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Page 3 of 9transferred to a well in a 24-well plate and the process was
repeated with other colonies. When wells were confluent,
they were split into one well of a 6-well plate (passage
number 20) with a lower amount of blasticidin for mainte-
nance (1 μg/mL). Cells were then assayed for knockdown
of the target gene in one of the clones.
Assay for knockdown of the iav-PK-15 cells
RNA isolation and real-time qRT-PCR [19]
Targeted gene expression was detected by establishing
iav-PK-15 cell lines at passage number 20, which were
cultured in DMEM supplemented with 10% heat inacti-
vated FBS, and total RNA was extracted from iav-PK-15
cell cultures using an RNeasy Mini Kit (Invitrogen),
before real-time qRT-PCR analysis using the SYBP RT-
PCR Kit (TaKaRa, Japan). Specific amplification was
confirmed by melting curve analysis of the real-time
qRT-PCR products, performed according to the manu-
facturer’s protocol. Fluorescence was measured after
each cycle and displayed graphically with a Stratagene
Real time PCR Mx3000p (USA). Beta actin was used as
a positive control and the avc D N Aw a sa m p l i f i e df r o m
cDNA preparations of iav-PK-15 cells by PCR using the
primers shown in Table 1. The PCR procedures fol-
lowed the manufacturer’s instruction, with the following
thermal profile: 10 s at 95°C for predenaturation; 40
cycles of 5 s at 95°C; and 20 s at different annealing
temperatures, depending on the integrins that were
amplified. The specific amplification was confirmed by
melting curve analysis of the real-time qRT-PCR pro-
ducts according to the manufacturer’s protocol, with the
following thermal profile: 1 cycle of 95°C for 60 s; 55°C
for 30 s; and 95°C for 30 s. PCR products were run on
3% agarose gel containing ethidium bromide and DNA
bands were visualized using a UV transilluminator.
IIF
Indirect immunofluorescence (IIF) assay was carried out
to detect expression of the targeted av protein on the
cell surface of an established iav-PK-15 cell line at pas-
sage number 20, which was cultured in DMEM supple-
mented with 10% heat inactivated FBS. Cells were grown
on acid-washed cover slips to ensure adherence of cells.
The culture media was carefully aspirated from the cul-
ture dish using a pipette, because vacuum aspiration
might also suck up cells from the cover slip surface. Cells
were fixed in 4% paraformaldehyde (PFA) for 20 min at
room temperature and were permeabilized for 5 min
with 0.1% triton X-100 in 1× PBS at room temperature.
Cells were then incubated in freshly prepared 50 mM
NH4Cl for 15 min to quench free aldehyde groups from
PFA, before fixation after washing three times with 1×
PBS. Cultures were blocked with 1% BSA in 1× PBS for
30 minutes at room temperature, before incubation with
primary antibody diluted in blocking buffer (1% BSA in
PBS) for 1 h at room temperature. After primary incuba-
tion, cover slips were returned to the dishes and washed
in PBS five to six times, for 5 min each wash. Secondary
incubation was for 1 h at room temperature. The diluted
antibody was centrifuged before use to pellet aggregates
and covered in foil to protect from light. A control was
included, which was comprised of the secondary antibody
alone. The cover slips were returned to the dish and
washed five times, for 5 min each wash using PBS, ensur-
i n gt h a ts a m p l e sw e r ep r o t e c t e df r o mt h el i g h t .C o v e r
slips were mounted by dipping the cover slips in distilled
w a t e rt or e m o v es a l tf r o mP B S ,b e f o r eb l o t t i n gt h ee d g e
using filter paper to dry off excess water, before placing
the cover slip cell-side down on a drop of mounting med-
ium on a glass slide. The mounting medium used was
DAPI (USA). The cover slip was stabilized on the slide
using nail lacquer and left to dry overnight before
viewing.
Indirect cell ELISA for adherent Cells
We added 100 μL of the cell suspension (1.0 × 10
5 cells in
each well of a 96-well culture plate) and incubated in 5%
CO2 at 37°C, for at least 24 h allowing cells to attach. We
removed the residual culture medium by inversion and by
gently tapping the inverted plate on a paper towel. We dis-
pensed the primary antibody (50 μL), which was diluted in
ice-cold ELISA buffer at the optimal concentration, whilst
holding the pipette tip against the walls of the wells, then
incubated for 1 h at 4°C. The unbound primary antibody
was removed by vacuum aspiration, whilst taking care
to avoid drying. The plate was washed by gently adding
200 μL of ice-cold washing buffer, whilst holding the pip-
ette tip against the wall of the well to prevent detachment
and loss of cells. The washing step was repeated four more
times. After the last washing, the washing buffer was
removed by inversion, whilst gently tapping the inverted
plate on a paper towel. We then added the HRP-conju-
gated to the specific antibody for the primary antibody
(50 μL) diluted in ice-cold ELISA buffer at the optimal
concentration before incubating the plate for 1 h at 4°C.
After five washings with PBS containing 1% BSA, 100 μL
of tetramethylbenzidine (TMB) substrate was added to
each well and incubation was continued for an additional
10 min at room temperature. We stopped the enzyme
reaction by adding 50 μLo f1 . 2 5MH 2SO4,a n dt h eo p t i c a l
Table 1 Primer sequences used in this study
Primer sequence Subunit Size Purpose
AF 5’-GATTGTTGTTACTGGCTGTTTTGG-3’ av 94 bp Real-time
PCR
AR 5’-TGTTCCCTTTCCTGTTCTTCTTG-3’
ACTF 5’-GGACTTCGAGCAGGAGATGG-3’ Β-actin 138 bp Real-time
PCR
ACTR 5’-AGGAAGGAGGGCTGGAAGAG-3’
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Reader; Labsystems, Helsinki, Finland) at A450 nm.
Viral challenge assay for the iav-PK-15 cells
Virus infectivity was determined by serial dilution of cell
samples grown in 96-well plates. The virus titer was cal-
culated as the 50% tissue culture infective dose (TCID50)
using the Reed-Muench formula [20]. A viral suspension
titrated at 10
4.41 TCID50 was used in the experiment.
Monolayers (about 50% confluent) were grown in 96-well
plates to assess the capacity of viruses to grow in PK-15
cells expressing siRNAs. Cells in one well of the 96-well
plates were infected with 100 TCID50 of virus per 0.1 ml.
After 1 h of adsorption, the inoculum was removed and
cells were washed twice with DMEM. The infection then
proceeded in DMEM supplemented with no-fetal bovine
serum and the virus titers were determined after two
days. Statistical analysis was performed with the Micro-
soft Excel program.
Results
Target gene expression of the porcine integrin av
subunit (the FMDV receptor) constructed with an RNAi
lentivirus vector and established as an iav-PK-15 cell line
We constructed the iav-pENTR™/U6 entry clone and
iav-pLenti6/BLOCK-iT™ expression clone by produ-
cing a lentiviral stock (containing the packaged iav-
pLenti6/BLOCK-iT™-DEST expression construct, or
the packaged pLenti6/BLOCK-iT™-DEST expression
construct) and co-transfecting the optimized Vira-
Power™ Packaging Mix (3.0 μg/μl) and iav-pLenti6/
BLOCK-iT™-DEST expression construct or pLenti6/
BLOCK-iT™-DEST expression construct (3 μg) into the
293FT producer cell line, then harvested the viral super-
natant, and determined the lentiviral stock titer with
blasticidin. We picked blasticidin-resistant clones and
cultured then in DMEM supplemented with 10% heat-
inactivated FBS at passage number 20. The sequencing
results demonstrated successful cloning of the iav-
pENTR™/U6 entry clone and the iav-pLenti6/BLOCK
-iT™ expression clone construct. The functional titer of
the virus obtained was 1.0 × 10
6 TU/mL. We estab-
lished stabled iav-PK-15 cells line at passage number
20, which inhibited target gene expression in the por-
cine integrin av subunit, the FMDV receptor.
Real-time qRT- PCR assay of inhibition of RNA replication
To demonstrate the level of inhibition, iav-PK-15 cells
were collected at passage number 20 and real-time qRT-
PCR analysis was performed (Figure 2). The level of the
av gene was determined by real-time qRT-PCR and signif-
icantly decreased by about 89.5% in iav-PK-15 cells. Out
results indicate that iav-PK-15 cells can effectively and
specifically target gene expression of the porcine integrin
av subunit, the FMDV receptor.
Level of inhibition of integrin av subunit expression by
IIF and indirect cell ELISA for adherent cells
Indirect immunofluorescence was used to visualize the
cells under a fluorescence microscope. Control and
mock exhibited a lot of green fluorescence, whereas sig-
nificant reduction was observed in the green fluorescent
signal of iav-PK-15, relative to the control and mock,
indicating that iav -PK-15 cells had inhibited expression
of the surface protein (Figure 3).
Cell ELISA was a useful technique for the quantitative
analysis of cell surface antigen expression and was a sensi-
tive, simple and reproducible method for detecting the cell
membrane antigen processing machinery components of
cells. Inhibition to target the gene expression of porcine
integrin av subunit, the FMDV receptor, was performed
to demonstrate that the reactivity of pAb located in the
membrane of cells was significantly inhibited (Figure 4).
E
D D
Figure 2 Downregulation of avm R N Ao fi av-PK-15 detected
with real-time qRT-PCR. Relative mRNA levels of av gene are
presented as the ratio of the av mRNA quantity and the 1 ng b-
actin (ng/1 ng b-actin) to facilitate comparison with the levels of
inhibition of the av gene. Data are shown as the average of three
repeated experiments. Error bars show standard deviations. There
was a highly significant difference between the control and mock,
and iav-PK-15 (P < 0.01).
Figure 3 Visualization of A. Mock (+++); B. Control (+++); and
C. iav-PK-15 (+), by IIF. Samples were incubated with primary
antibody (rabbit av integrin, 1:500) with mouse anti-rabbit IgG-FITC
(1:200). Negative (-), no fluorescent cells; weakly positive (+), the
signal was faint (less than 5% of cells); positive (++), 5% to 50%
were readily detected; strongly positive (+++), positive staining was
intense in more than 50% of cells.
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The antiviral activity was tested using cell monolayers in
96-well plates, where100 aL of the cell suspension (1.0 ×
10
5 cells in each well of a 96-well culture plate) was incu-
bated in 5% CO2, at 37°C, allowing at least 24 h for cells
to attach. Cells were infected with 100 μl of 100 TCID50
FMDV O/CHA/99 and observed microscopically after 48
h. Viral infection caused a marked cytopathic effect
(CPE) culminating in total cellular detachment, rounding
up, and destruction, which was observed by microscopy
[21]. The virus in the supernatant was titrated for infec-
tivity using iav-PK-15 cells. After 48 h, viral titers
decreased from 10
4.39,1 0
4.41 in control and mock to
10
1.29 TCID50 in iav-PK-15 cells. SiRNAs inhibited virus
yield by greater than 1000-fold and there was a > 99%
reduction in virus titer (Figure 5).
Discussion
FMDV is the prototypic member of the Aphthovirus
genus of the Picornaviridae family. The viral capsid is
made up from 60 copies each of four viral encoded pro-
teins, VP1 to VP4: VP1, VP2 and VP3 form the outer
clasped shell; and VP4 makes up the interior surface [22].
FMDV enters the cell by receptor-mediated endocytosis,
in a process that begins with the initial attachment of the
virus to cell-surface receptors. The G-H loop forms a
major antigenic site on the virion, which includes at its
apex an Arg-Gly-Asp (RGD) motif [23,24], a sequence
that has been implicated in receptor binding on the basis
of synthetic peptide inhibition studies [25]. FMDV can
enter cells using different pathways; the main pathway is
by binding integrins via a conserved RGD located within
the GH loop of VP1 [26,27]. One subgroup within the
integrin family is the av integrin, which recognizes RGD
as a binding motif on natural ligands. The av subunit is
subdivided into two groups based on certain structural
differences [28]. The first group is formed by a-1, a-2, a-
L, a-M, and a-X. The second group is formed by a-3, a-
5, a-6, a-7, a-8, a-IIb, a-V and a
IEL. 24 functional integ-
rins have been identified in mammalian species, which
result from different pairings among 18 a subunits and 8
b subunits [29]. Different integrins have roles as FMDV
receptors (avb1, avb3, avb6, avb8) [30]. Members of
this group all undergo post-translational cleavage of their
precursor into a heavy and a light chain. The light chain
is composed of the cytoplasmic domain, the transmem-
brane region, and a part of the extracellular domain
(about 25 kDa), whilst the heavy chain contained the rest
of the extracellular domain (about 120 kDa) [31].
RNAi is a powerful gene silencing mechanism operating
in most eukaryotic cells [32]. The effector molecules com-
prise short duplex RNA sequences of 21-23 bp that direct
inhibition of homologous genes. This natural pathway is
important for processing of regulatory micro RNAs (miRs)
[33]. FMDV is antigenically highly variable and consists of
seven serotypes and multiple subtypes [34] that underlie
the rapid spreading nature of the clinical disease as early
as 2-3 days post-exposure. This means that there is a need
to develop new tools that provide early protection, thereby
containing the disease spread. RNAi is used as an antiviral
technology and has been widely studied for its affect on
FMDV [9,35,36]. A multiple-siRNA expression system was
developed that focused on several regions of the viral gen-
ome [37]. Focusing on the conserved regions of the viral
genome [38,39], or simultaneously targeting several viral
sequences are different approaches to resolving this issue.
The multiple-siRNA-expressing plasmid, the pCWN11
Figure 4 Expression effects of integrin av, as detected by cell
ELISA method. Cells (1.0 × 10
5) were incubated with the isotype-
matched pAb (av integrin, 1:500) with peroxidase-conjugated
mouse anti-rabbit IgG (1:10 000), and TMB. Error bars indicate
standard deviations. There was a highly significant difference
between the control and mock, and iav-PK-15 (P < 0.01).
D D
E
Figure 5 Decrease in virus yield of iav-PK-15 cells. Cells (control,
mock, and iav-PK-15) were infected with 100 TCID50 of FMDV O/
CHA/99 per 0.1 ml. The virus titer (TCID50) was determined three
times. Error bars indicate standard deviations. There was a highly
significant difference between the control and mock, and iav-PK-15
(P < 0.01).
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genetic variability in FMDV and viral escape [40,41]. This
approach may be used to deal with several viruses, which
would be especially useful in the treatment of coinfections
by multiple pathogens [8]. Current measures for the con-
trol of FMD outbreak include routine vaccination, control
of animal movement, and slaughter. FMD vaccines based
on inactivated virus and adjuvants are effective in eliminat-
ing the disease, but risk the escape of live viruses from ani-
mal facilities or as a consequence of improper vaccine
preparations [33,42]. The development of a recombinant
peptide vaccine [43] and a synthetic peptide vaccine [44])
both of which are safe and effective, has been reported.
The limited effectiveness of existing vaccines and antiviral
drugs means the development of new strategies is essen-
tial. The RNAi approach has been reported as an ideal
tool to inhibit infectious virus replication in host cells,
because siRNA can target and silence important viral
genes. However, RNA viruses are likely to evolve mechan-
isms to suppress or escape an RNAi response. Long-term
silencing of viral protein expression by siRNAs has been
reported to result in the emergence of viruses resistant to
RNA interference [40,45]. In particular, integrin av-het-
erodimers have been previously shown to mediate cellular
entry of field strains of the virus. In contrast, cell surface
expression of ab3 or mRNA for the ab1, ab3o rab5s u b -
units did not appear to contribute to sensitivity of cells to
FMDV [46]. We constructed an RNAi lentiviral vector to
inhibit target gene expression of the porcine integrin av
subunit, the FMDV receptor.
It was previously shown that siRNAs inhibited virus
yield by 10-fold to 1000-fold. The level of viral replication
(IND 63/72) inhibition varied depending on the siRNAs
produced by the Cocktail Kit. Here, the maximum inhibi-
tion (120-fold reduction in virus titer) was observed with
the 2A-2C product compared with both VP3-VP1 (100-
fold reduction in virus titer) and 3D-3’ UTR (40-fold
reduction in virus titer) at 24 h. In this case, there was a
> 99% reduction in virus titer with all the serotypes up to
24 h [47]. pCWN11 was a plasmid constructed to express
siRNAs with multiple-targeting of the VP1 genes in
FMDV. To investigate the effect of pCWN11 on FMDV
replication, approximately 10
3 TCID50 of HKN/2002
virus progeny was detected in the supernatant and col-
lected from cells transfected with pCWN11 at 19 h p.i.
Over 10
5 TCID50 of virus was determined in the superna-
tant collected from control cells [8]. However, a 1000-
fold reduction was found in virus titer 24 h post-infection
of BHK cells expressing small hairpin RNA (shRNA)
under the control of a mouse U6 promoter from a plas-
mid construct [35]. We observed a significant cross-inhi-
bition of FMDV replication in BHK-21 cells by siRNAs
targeted at various conserved regions of the viral genome
( 5 V N C R ,V P 4 ,V P g ,P O L ,a n d3 V N C R ) .T h er e s u l t s
showed that siRNAs generated in vitro by human recom-
binant dicer enzyme resulted in a viral yield inhibition of
10-fold to 1000-fold in both homologous (HKN/2002)
and heterologous (CHA/99) isolates of FMDV serotype
O at 48 h post-infection [13]. A sequence corresponding
to the critical 30 bp region that forms a stem-loop struc-
ture in IRES was also selected for investigation. The
regions selected for shRNA were designated as D1, D2,
D3, and D4. The virus in the supernatant was titrated in
BHK-21 cells to determine infectivity. At 12, 18, and
24 h, the D4-transfected cells yielded a viral titer (10
-5
TCID50) that was almost equal to the control. The virus
titer in the D2- and D3-transfected cells was less than
10
-2 TCID50 at 18 and 24 h. D1-transfected cells yielded
10
1.4,1 0
1.7,a n d1 0
2.9 TCID50 at 12, 18, and 24 h, respec-
tively [48]. Kahana et al. demonstrated 100% inhibition of
virus growth in BHK-21 cells transfected with a mixture
of several anti-FMDV siRNAs [49]. In this study, there
was reduction in virus titer of greater than 1000-fold in
iav-PK-15 cell for O/CHA/99. The results indicate that
the reduction in virus titer was either better than the pre-
vious study or showed the same effect.
In this study, we constructed an RNAi lentiviral vector
containing the packaged iav-pLenti6/BLOCK-iT™-DEST
expression construct to inhibit target gene expression of
the porcine integrin av subunit, the FMDV receptor. We
co-transfected the ViraPower™ Packaging Mix and the
iav pLenti6/BLOCK-iT™-DEST expression construct
containing the U6 RNAi cassette into 293FT cells to pro-
duce a replication-incompetent lentivirus, which was
transduced into the mammalian cell line of interest. Once
the lentivirus enters the target cell the viral RNA is
reverse-transcribed, actively imported into the nucleus,
and stably integrated into the host genome. The lentiviral
construct contains a deletion in the 3’ LTR that leads to
self-inactivation of the lentivirus after transduction into
mammalian cells. Once the lentiviral construct has inte-
grated into the genome, the lentivirus can no longer pro-
duce packageable virus and the shRNA of interest is
constitutively expressed allowing the performance of tran-
sient RNAi analysis, or blasticidin selection to generate a
stable cell line for long-term knockdown studies. To deter-
mine whether this system can be used to inhibit gene
expression of the integrin av subunit gene, the expression
construct and packing plasmid were transduced into PK-
15 cells, and we then established an iav-PK-15 cell line.
We found that co-transduction resulted in a significant
reduction in the corresponding integrin av subunit tran-
scription by real-time qRT-PCR, and integrand avs u b u n i t
expression by cell ELISA and IIF. Cell ELISA is a useful
technique for the quantitative analysis of cell surface anti-
gen expression, which was developed on the basis of
enzyme immunohistochemistry (EIH) and ELISA. Since its
development, which was facilitated by the establishment of
Luo et al. Virology Journal 2011, 8:428
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Page 7 of 9monoclonal antibody technology, a wide range of cell
types and surface molecules have been analyzed by cell
ELISA, and other methods for the quantitative detection
of cell surface molecules. Cell ELISA is not appropriate for
analyzing mixed-cell populations. In cell ELISA, labeling
of immunoreactant molecules is achieved using an
enzyme, such as horseradish peroxidase (HRP). IIF is a
rapid sensitive method, which uses cell culture for the
detection of integrin av subunit expression in cell surface.
At present, there is no information available; further work
is needed to test the relationship between anti-FMDV effi-
ciency and integrand b1, b3, b6a n db8.
Conclusion
Our results suggest that the interference integrin avs u b u -
nit expressing system is a feasible strategy for overcoming
the issue of high genetic variability of FMDV, and viral
escape. This approach may be developed to combat several
viruses, which would be especially useful in the treatment
of co-infections by FMDV. In addition, the new strategy
would be beneficial in combating viruses with a high viral
mutation rate. Our study provides a foundation for the
cultivation of new varieties of transgenic organisms. How-
ever, this work represents a significant advancement,
describing a new approach to trigger anti-FMDV pathways
through inhibiting the FMDV receptor gene expression of
the porcine integrin av subunit.
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